Sociedad Americana de Hirudoterapia

Structure-activity relationships of recombinant hirudins

Review published in Seminars in Thrombosis and Hemostasis (1991)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyDesarrollo de fármacosFarmacología salivalStürzebecher J, Walsmann P · Seminars in thrombosis and hemostasis, 1991

Abstract

The complex formation between thrombin and hirudin is unique among other serine proteinase-inhibitor complexes. The serpines occupy the specificity pocket of the active site of the target enzyme with an amino acid residue corresponding to the specificity of the enzyme at the P1 site of the substrate. In contrast, the Thr2 residue of hirudin approaches only the entrance of the pocket. The peptide chain of the inhibitors D-Phe-Pro-ArgCH2Cl and NAPAP is antiparallel to the enzyme backbone, whereas the N-terminal amino acids of hirudin run parallel. These unexpected interactions seem to contribute to a greater extent to the tight binding than the ionic interactions of the hirudin tail with the fibrinogen binding site of thrombin. Obviously, these interactions account for the unique selectivity of hirudin for thrombin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleReview
Indexed MeSH termsAmino Acid SequenceBinding SitesFibrinogenHirudinsModels, MolecularMolecular Sequence DataPeptide FragmentsProtein BindingRecombinant Fusion ProteinsStructure-Activity RelationshipThrombin

Resumen

Reviews how recombinant hirudin's N-terminal Thr2 contacts the active-site entrance running parallel to thrombin's backbone, while ionic interactions of the C-terminal hirudin tail with thrombin's fibrinogen binding site provide additional selectivity.

Por qué esto importa para la hirudoterapia

This work examines the molecular interactions in the complex formation between thrombin and hirudin, describing how hirudin's N-terminal amino acids run parallel to the enzyme backbone—in contrast to other serine proteinase-inhibitor complexes—and how the Thr2 residue approaches only the entrance of the specificity pocket. The abstract indicates these interactions contribute more to tight binding than the ionic interactions of the hirudin tail with the fibrinogen binding site of thrombin, accounting for hirudin's unique selectivity for thrombin. This is relevant to ASH's domain as it provides molecular-level insight into the hirudin-thrombin interaction. Caveat: the scope is limited to biochemical and molecular characterization, with no clinical, whole-organism, or therapeutic application data presented.

Citación

Structure-activity relationships of recombinant hirudins.

Stürzebecher J, Walsmann P · Seminars in thrombosis and hemostasis, 1991

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.